Sheet 1 Over 75 types of human papilloma viruses (HPV) have been typed at the DNA level, and these can be broadly grouped into families on the basis of their tissue tropism.
Histologic, molecular, and epidemiologic evidence have implicated some HPV strains in cervical dysplasia and cervical cancer. Many Studies Support the View that most moderate and Severe cervical intraepithelial neoplasiaS (CIN) contain HPV DNA which is exclusively detected in the histologically abnormal epithelium of these lesions. Persistent infection with HPV is believed to be the predomi nant risk factor for development of cervical carcinoma. HPV DNA is readily found in episomal form within cells exhib iting a cytopathic effect, while the HPV DNA is found integrated within the chromosomes of cells associated with most high grade precancerous lesions and cancer. Approxi mately 23 HPV types are commonly found in anogenital Screening programs, but only 10-15 are associated with progressive disease. Type 16 is the type most commonly found in cervical cancer tissue.
Papillomaviruses contain nine open reading frames. HPV genes with transforming properties have been mapped to open reading frames E6 and E7. Substantial biochemical work has demonstrated that the HPV E6 protein inactivates the protein p53, whereas the E7 protein interferes with retinoblastoma (Rb) protein function. Since p53 and Rb are tumor-Suppressor proteins which function as cell division inhibitors, their inactivation by E6 and E7 leads the cell to enter into S phase of the cell cycle. Expression of E6 and E7 is Sufficient to immortalize Some primary cell lines, and blocking E6 or E7 function has been shown to reverse the transformed State.
SUMMARY OF THE INVENTION
The invention is based on the discovery that a 13 amino acid peptide from the HPV strain 16 E7 protein that contains overlapping class I HLA binding, T cell epitopes can induce a CTL response in an animal. Accordingly, the invention includes an immunogenic peptide having within its Sequence multiple class I MHC-binding epitopes from a human pap illomavirus (HPV) protein, and which has a length of less In addition, all of the peptides discussed herein may include additional amino acids to facilitate expression, e.g., an amino terminal methionine to facilitate translation.
The invention also includes a polypeptide having the Sequence of a first peptide linked to a Second peptide by a peptide bond. The first peptide (which can be at the carboxy terminus or the amino terminus of the Second peptide, So long as it functions in that Site) is a peptide which controls intracellular trafficking of a peptide to which it is attached, and the Second peptide is the immunogenic peptide described above. The polypeptide may optionally be modi fied to introduce an amino acid Substitution at the junction between the first and Second peptides to promote cleavage of the first and Second peptides by a signal peptidase.
The Another way to administer the peptide utilizes a nucleic acid, e.g., an expression Vector, comprising a coding Sequence encoding the immunogenic peptide. The nucleic acid can optionally encode a Signal Sequence linked to the immunogenic peptide, as described above. When the nucleic acid encodes Such a signal Sequence, it is preferred that it encodes the signal sequence from HLA-DRC. (SEQ ID NO:18) . In Such a case, the immunogenic peptide can have the sequence, for example, of SEQ ID NO:4 or SEQ ID NO:3. Preferably, the nucleic acid does not include Sequences from a viral genome that would render the nucleic acid infectious, and does not encode an intact E7 protein.
The nucleic acid described above can be included in a plasmid, optionally provided in a microparticle that also includes a polymeric matrix. In preferred embodiments, the polymeric matrix consists essentially of a copolymer of PLGA. The microparticle preferably has a diameter of, e.g., 0.02 to 20 microns, or less than about 11 microns. A plurality of microparticles preferably has diameter of, e.g., 0.02 to 20 microns, or less than about 11 microns Also within the invention is a cell containing the plasmid of the invention. The cell can, e.g., be a B cell or other antigen presenting cell (APC). The cell may be cultured or US 6, 183, 746 B1 3 otherwise maintained under conditions permitting expres Sion of the peptide from the plasmid encoding it.
The nucleic acid and plasmid of the invention are useful in a method of inducing an immune response in a mammal, e.g., a human, by administering the above-described plasmid to the mammal, e.g., as "naked DNA'. The mammal may be at risk for, or suffer from, HPV infection, cervical dysplasia, and/or cervical cancer. The nucleic acids and plasmids of the invention can also be incorporated into microparticles, liposomes, ISCOMS, or any other suitable delivery vehicle as described above.
The invention further includes a plasmid having a Sequence essentially identical to that of pBIOTOPE, (SEQ ID NO:7), or a microparticle consisting essentially of a PLGA polymeric matrix and the pBIOTOPE plasmid, as well as methods of inducing an immune response in a mammal by administering either the plasmid alone, or the plasmid incorporated into Such a microparticle, to the mam mal.
By a "Substantially pure polypeptide' is meant a polypep tide which is separated from those components (proteins and other naturally-occurring organic molecules) which natu rally accompany it. Typically, the polypeptide is Substan tially pure when it constitutes at least 60%, by weight, of the protein in the preparation. Preferably, the protein in the preparation consists of at least 75%, more preferably at least 90%, and most preferably at least 99%, by weight, of an immunogenic peptide.
Unless otherwise defined, all technical and Scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The preferred methods and materials for practicing the invention are described below, although other methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention. All publications, patent applications, patents, and other references mentioned herein are incorpo rated by reference in their entirety. In case of conflict, the present application, including definitions, will control. The materials, methods, and examples are illustrative only and not intended to be limiting.
Other features and advantages of the invention will be apparent from the following detailed description, and from donor stimulated with an influenza peptide (--), the A2.1 peptide (--), or the A2.4 peptide (-A-).
DETAILED DESCRIPTION
The peptides disclosed herein, and the nucleic acids encoding the peptides, can be used to elicit an immune response against the HPV E7 protein. A peptide of the invention may optionally include one having the amino acids SOK added to the carboxy terminus of the A2.4 peptide sequence ("the extended peptide').
Processing of the extended peptide can generate the peptide IVCPICSQK (SEQ ID NO:22), which has been reported as binding the MHC class I molecules HLA-A3 and HLA-A11 (Kast et al., J. Immunol. 152:3904-11, 1994) . This region of the HPV E7 protein has several peptides that can be pro cessed into MHC binding peptides. Additional extensions to the amino or carboxy terminus of the A2.4 peptide may further increase the number of peptides that can be generated from this region of the E7 protein.
The peptides of the invention can be linked to a trafficking Sequence that directs the peptides to a desired intracellular compartment. A trafficking Sequence is an amino acid Sequence which functions to control intracellular trafficking (directed movement from organelle to organelle or to the cell Surface) of a polypeptide to which it is attached. Such Ile Ile Ala Val Leu Met Ser Ala Gln Glu Ser Trp Ala (SEQ ID NO:18). The signal peptide may include only a portion (e.g., at least ten amino acid residues) of the specified 25 residue Sequence, provided that portion is Sufficient to cause trafficking of the polypeptide to the ER.
In Some cases it is desirable to modify the portion of the peptide Spanning the trafficking Sequence and the Sequence encoding the HPV E7 antigenic peptide to facilitate processing, i.e., cleavage, by the Signal peptidase. Recog nition Sequences for Signal peptides are described in Von Heijne, NAR 14:4683, 1986 .
Standard techniques can be used to construct a DNA encoding the antigenic peptide (See, e.g., the techniques described in WO 94/041.71). The construct may include Also within the plasmid is a kanamycin resistance gene (positions 519-1313), which is driven by the SV40 early promoter (positions 131-484) and which has a thymidine kinase (TK) polyadenylation site (positions 1314-1758).
The kanamycin resistance gene and accompanying regula tory Sequences are for Selection purposes only and can be removed from the plasmid if Selection is not required or desired.
Once expressed in a cell, the encoded peptide can be processed into one of several HLA MHC class I binding Table 1 . These peptides can bind the HLA-A2 allele and may also bind other alleles, such as HLA-A1, HLA-A3, HLA-A11, HLA-A24. The MHC molecule, upon binding to the peptide, can activate a T cell response. MHC class II binding peptides may also be generated from the encoded peptide. These peptides would be expected to activate Thelper cells or CTL upon presentation by the MHC class II expressing cells. Other receptorS may also bind the encoded peptide or its processed fragments to activate immune cells Such as NK or B cells. These cells may also be activated by cytokines elicited in response to the peptides of the invention.
The peptides and nucleic acids of the invention can be used as vaccineS prophylactically or therapeutically in Sub jects known to be infected by HPV, Suspected of being infected by HPV, or likely to become infected by HPV. Other Suitable Subjects include those displaying Symptoms of, or likely to develop, HPV-associated conditions. The immuno genic peptides, and nucleic acids encoding these peptides, can be used as vaccines in preventing or treating conditions associated with infections of HPV strain 16, e.g., bowenoid papulosis, anal dysplasia, respiratory or conjunctival papillomas, cervical dysplasia, cervical cancer, Vulval cancer, or prostate cancer. They can also be used to treat conditions associated with other HPV strains, especially those associated with HPV strains 18, 45, 6, 11, 35 and 31, which have regions of homology to the peptide of SEQ ID NO:3. These conditions include, e.g., exophytic condyloma (HPV strains 6 and 11), flat condyloma, especially of the cervix (HPV strains 6, 11, 16, 18, and 31), giant condyloma (HPV strains 6 and 11), cervical cancer (HPV strains 18, 31, and 33, in addition to HPV strain 16), respiratory and conjunctival papillomas (HPV 6 and 11), and infection with genital-tract HPVs (HPV 6, 11, and 16).
The immunogenic peptides or nucleic acids encoding the peptides can administered alone or in combination with other therapies known in the art, e.g., chemotherapeutic regimens, radiation, and Surgery, to treat HPV infections, or diseases associated with HPV infections. In addition, the peptides and nucleic acids of the invention can be admin istered in combination with other treatments designed to enhance immune responses, e.g., by co-administration with adjuvants or cytokines (or nucleic acids encoding cytokines) as is well known in the art.
The peptides or nucleic acids of the invention can also be used in manufacture of a medicament for the prevention or treatment of HPV infection, or conditions associated with HPV infection.
Delivery of Immunuogenic Peptides and Nucleic Acids Encoding Immunogenic Peptides
The delivery systems of the invention may be used to deliver, into appropriate cells, peptides, or DNA constructs which express peptides, intended to Stimulate an immune response against HPV. An advantage of DNA delivery is that the antigenic peptide is produced inside the target cell itself, where the interaction with a class I or class II MHC molecule to which the immunogenic peptide binds is kineti cally favored. This is in contrast to Standard Vaccine proto cols which do not specifically direct antigenic peptides to MHC molecules. In addition, the immune response directly stimulated by DNA vaccines of the invention is likely to be limited to a T cell mediated response, in contrast to Standard vaccine protocols which result in a more generalized immune response, although it is possible that an antibody response may be indirectly induced when cells bearing viral particles are killed, or by other mechanisms.
The immunogenic peptides, or nucleic acids encoding the peptides, can be administered using Standard methods, e.g., 7 those described in Donnelly et al., J. Imm. Methods 176:145, 1994, and Vitiello et al., J. Clin. Invest. 95:341, 1995. Peptides and nucleic acids of the invention can be injected into Subjects in any manner known in the art, e.g., intramuscularly, intravenously, intraarterially, intradermally, intraperitoneally, intranasally, intravaginally, intrarectally or Subcutaneously, or they can be introduced into the gas trointestinal tract, the mucosa, or the respiratory tract, e.g., by inhalation of a Solution or powder containing the micro particles. Administration can be local (e.g., at the cervix or other site of infection) or Systemic.
The immunogenic peptides and nucleic acids encoding immunogenic peptides can be delivered in a pharmaceuti cally acceptable carrier Such as Saline, lipids, lipoSomes, microSpheres, nanospheres, as colloidal Suspensions, or as powders. They can be naked or associated or complexed with delivery vehicles and delivered using delivery systems known in the art, Such as lipids, liposomes, microparticles, gold, nanoparticles, polymers, condensing agents, polysaccharides, polyamino acids, dendrimers, Saponins, adsorption enhancing materials, or fatty acids.
It is expected that a dosage of approximately 0.1 to 100 tumoles of the polypeptide, or of about 1 to 200 tug of DNA, would be administered per kg of body weight per dose. Where the patient is an adult human, Vaccination regimens can include, e.g., intramuscular, intravenous, oral, or Sub cutaneous administrations of 10-1000 tug of pBIOTOPE, DNA when delivered in a microparticle, or of about 100-1000 tug of naked pBIOTOPE DNA delivered intra muscularly or intradermally, repeated 3-6 times. Of course, as is well known in the medical arts, dosage for any given patient depends upon many factors, including the patient's size, body Surface area, age, the particular compound to be administered, Sex, time and route of administration, general health, and other drugs being administered concurrently. Determination of optimal dosage is well within the abilities of a pharmacologist of ordinary skill.
Other Standard delivery methods, e.g., biolistic transfer, or They contain macromolecules embedded in a polymeric matrix or enclosed in a shell of polymer. Microparticles act to maintain the integrity of the macromolecule e.g., by maintaining enclosed DNA in a nondegraded State. Micro particles can also be used for pulsed delivery of the macromolecule, and for delivery at a specific Site or to a Specific cell or target cell population.
The polymeric matrix can be a biodegradable co-polymer Such as poly-lactic-co-glycolic acid, Starch, gelatin, or chitin. Microparticles can be used in particular to maximize delivery of DNA molecules into a subject's phagocytotic cells. Alternatively, the microparticles can be injected or implanted in a tissue, where they form a deposit. AS the deposit breaks down, the nucleic acid is released gradually over time and taken up by neighboring cells (including APCs) as free DNA. The ability of immunogenic peptides, or nucleic acids encoding the Same, to elicit an immune response can be assayed by using methods for measuring immune responses that are well known in the art. For example, the generation of cytotoxic T cells can be demonstrated in a standard 'Cr release assay, by measuring intracellular cytokine expression, or by using MHC tetramers. Standard assays, Such as ELISA or ELISPOT, can also be used to measure cytokine profiles attributable to T cell activation. T cell proliferation can also be measured using assayS Such as H-thymidine uptake and other assays known in the art. B cell responses can be measured using art recognized assays Such as ELISA.
Other methodologies, e.g., digital imaging, cytologic, colposcopic and histological evaluations, can also be used to evaluate the effects of immunogenic peptides, and of nucleic acids encoding the immunogenic peptides, on papilloma Virus-associated lesions, or on papilloma virus levels gen erally.
The following are examples of the practice of the inven tion. They are not to be construed as limiting the Scope of the invention in any way.
EXAMPLES
AS described in the Examples below, experimental mod els were chosen to demonstrate the generation of vigorous CTL responses to plasmids encoding the immunogenic peptides of the invention, e.g., pBIOTOPE.
Initial Screening of HPV peptide Sequences was per formed by assessing binding affinity to the human class I HLA-A2 molecule. This was done by measuring the changes in circular dichroism (CD) as the receptor/ligand complex "melted'. Examples of this type of Screening are shown in Example 1. Of particular interest in Example 1 was the hybrid peptide A2. "/4, which contains at least two known epitopes.
Using a murine transgenic model, plasmids containing minigenes encoding these peptides were evaluated for their ability to generate HLA-A2 restricted CTLS (Examples 2 and 3). CTL activity, as measured using human target cells labeled with HPV peptides, was significantly increased over control targets for both the plasmids encoding A2.4 and A2.4, including the pa2.4 plasmid delivered in a PLGA microparticle.
Example 1 nant HLA-A2 or HLA-A3 was produced in E. coli and refolded in the presence of the HPV-derived peptides and purified human fi-microglobulin. The resulting peptide HLA complexes were then further purified by HPLC. To determine the precise thermokinetic interaction energy between receptor and ligand, each complex was "melted' while its structure was monitored by circular dichroism. The temperature required to "melt the complex is an accurate indication of the affinity between receptor and ligand.
The results of the binding studies are shown in Table II . ICs represents tha amount (nM) of peptide required for 50% inhibition of binding of a radiolabeled standard peptide to HLA-A*0201 or HLA A*0301 measured in a molecular binding assay. 0 Values represent the temperature in degrees Celsius at which 50% of the refolded complexes are melted. HLA-A2 and HLA-A3 will not refold in the absence of a peptide ligand of sufficient affinity.
Of particular interest is a hybrid peptide A2.4, which contains at least two known overlapping epitopes, A2.1 and A2.4, each of which is presented by HLA-A2 positive human cervical tumor cells expressing the HPV 16 E7 protein (Ressing et al., J. Immunology 154:5934, 1995) . Of the peptides Studied, A2.4 is predicted to be the most capable of eliciting cross reactive immune responses between HPV Strains. Moreover, the hybrid peptide generates both the A2.1 and A2.4 peptides; administration of p3IOTOPE to mice was found to generate T cell responses to both immu nogenic peptides. (Table III) . Mice immunized with a plasmid encoding the A2.4 pep tide generate CTL that lyse human targets expressing HLA A2 and the appropriate HPV peptide. This response is Significantly greater than that achieved by immunization with null vector DNA alone.
Example 3
Plasmid DNA Encoding the A2.4 Peptide Delivered to Mice in PLGA Microparticles Elicits CTL Responses 6-8 week old HLA-A2/K females were immunized intraperitoneally one time with 2-5 ug of PLGA micropar ticles containing plasmid pBIOTOPE. Seven days fol lowing the immunization, Splenocytes were harvested and in vitro stimulated with IL-2. After 2 days, CTL activity was measured on human targets labeled with HPV peptides (HPV(+)), or lacking HPV peptide (HPV(-)), at an E:T ratio of 50:1 (Table IV) . Thus, mice immunized with PLGA microparticles con taining pBIOTOPE generate CTL that lyse human tar gets expressing HLA-A2 and A2.4 peptide. stimulation were CD8". Overall, 3.1% of the PBMC receiv ing a final pulse of the A2.4 peptide were activated CTL, i.e., were CD8" CD16. IFN-y", compared to 0.5% of the cells receiving no final pulse of HPV-derived peptide.
For cells treated with the influenza peptide, 11.5% of the cells receiving a third Stimulation with the influenza peptide were positive for interferon Y, compared to 1.7% of the cells that did not receive a third stimulation. For cells cultured with influenza peptide, 11.5% of the cells given a final pulse of influenza peptide were activated, compared to 1.49% of cells which were not given a final pulse of influenza.
FIGS. 3 and 4 demonstrate that CTL specific for the A2.1 or A2.4-C peptides can recognize and lyse HPV 16-infected cells . FIG. 3 shows CTL-mediated lysis of an HLA-A2, HPV-16" transformed line (Caski) by T cell populations exposed to peptide A2.1, A2.4-C, or a peptide derived from influenza virus ("Flu'). Effector/target (E/T) ratios ranging from 25 to 1.5 were used. The peptide A2.4-C was highly effective at inducing lysis, with nearly 35% release detected at an E/T ratio of 25:1. The A2.1 peptide was less effective, but nevertheless caused much higher percentages of lysis at E/T ratios of 25:1 and 12:1 than did the influenza peptide.
Results with PBL isolated from a second HLA-A2" individual and subjected to two rounds of stimulation with peptide A2.1, peptide A2.4, or the influenza peptide ("Flu') are shown in FIG. 4 . Both the A2.1 and A2.4 peptides induced higher levels of lysis than did the influenza peptide.
These observations demonstrate that the A2.4 peptide, or peptides derived thereform, can activate and expand PBL from humans, and that these peptides can cause CTL mediated lysis of target cells transformed with HPV 16.
Other Embodiments
It is to be understood that while the invention has been described in conjunction with the detailed description thereof, that the foregoing description is intended to illus trate and not limit the Scope of the appended claims. Other aspects, advantages, and modifications are within the Scope of the following claims. What is claimed is:
1. A method of making a polypeptide, which method comprises maintaining a cell containing a plasmid compris ing a coding Sequence coding for expression of a polypep tide under conditions permitting expression of Said polypeptide, the polypeptide comprising a first peptide and a Second peptide linked by a peptide bond, the first peptide being a peptide which controls intracellular trafficking of a peptide to which it is attached, and the Second peptide consisting of a Sequence 12-18 amino acids in length comprising the sequence Leu Met Gly Thr Leu Gly Ile Val Cys Pro Ile Cys (SEQ ID NO:16).
2. A method of making a polypeptide, which method comprises maintaining a cell containing a plasmid compris ing a coding Sequence coding for expression of a polypep tide under conditions permitting expression of Said polypeptide, the polypeptide comprising a first peptide and a Second peptide linked by a peptide bond, the first peptide being a peptide which controls intracellular trafficking of a peptide to which it is attached, and the Second peptide consisting of a Sequence 8-18 amino acids in length com prising the sequence Thr Leu Gly Ile Val Cys Pro Ile (SEQ ID NO:20) . 9. The method of claim 8, wherein the human Suffers from, or is at risk of a condition Selected from the group consisting of eXophytic condyloma, flat condyloma, cervical cancer, respiratory papilloma, conjunctival papilloma, genital-tract HPV infection, and cervical dysplasia.
10. A method of inducing an immune response in a mammal, which method comprises administering to a mam mal a microparticle comprising (a) a polymeric matrix; and (b) a plasmid comprising a coding Sequence coding for expression of a polypeptide comprising a first peptide and a Second peptide linked by a particle bond, the first peptide being a peptide which controls intracellular trafficking of a peptide to which it is attached, and the Second peptide consisting of a Sequence 8-18 amino acids in length comprising the Sequence Thr Leu Gly Ile Val Cys Pro Ile (SEQ ID NO:20).
11. The method of claim 10, wherein the mammal is a human.
12. The method of claim 11, wherein the human Suffers from, or is at risk of, a condition Selected from the group consisting of eXophytic condyloma, flat condyloma, cervical cancer, respiratory papilloma, conjunctival papilloma, genital-tract HPV infection, and cervical dysplasia.
13. A method of inducing a cell mediated, anti-HPV immune response in a mammal, which method comprises administering to the mammal a DNA comprising the sequence of SEQ ID NO:7.
14. A method of inducing an immune response in a patient, which method comprises administering to the patient a microparticle having a diameter of less than 20 microns and consisting essentially of a polymeric matrix and a nucleic acid molecule, wherein the polymeric matrix consists essentially of PLGA and the nucleic acid molecule comprises the sequence of SEQ ID NO:7.
15. A method of inducing an immune response in an mammal, which method comprises administering a nucleic acid comprising a coding Sequence coding for expression of a peptide less than 19 amino acids in length, wherein the peptide comprises the amino acid Sequence Leu Met GlyThr Leu Gly Ile Val Cys Pro Ile Cys (SEQ ID NO:16). 81. The method claim 77, wherein the mammal is a human.
